Todd Bartkowiak
Overview
Explore the profile of Todd Bartkowiak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
719
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Voss K, Bartkowiak T, Sewell A, Chi C, Landis M, Schaefer S, et al.
Immunohorizons
. 2024 Jul;
8(7):492-499.
PMID: 39008056
The transcription factor FOXN1 plays an established role in thymic epithelial development to mediate selection of maturing thymocytes. Patients with heterozygous loss-of-function FOXN1 variants are associated with T cell lymphopenia...
2.
Bartkowiak T, Brockman A, Mobley B, Harmsen H, Moots P, Merrell R, et al.
medRxiv
. 2024 Jan;
PMID: 38234786
Congenital DNA mismatch repair defects (dMMR), such as Lynch Syndrome, predispose patients to a variety of cancers and account for approximately 1% of glioblastoma cases. While few therapeutic options exist...
3.
Bartkowiak T, Lima S, Hayes M, Mistry A, Brockman A, Sinnaeve J, et al.
JCI Insight
. 2023 May;
8(12).
PMID: 37192001
Radiographic contact of glioblastoma (GBM) tumors with the lateral ventricle and adjacent stem cell niche correlates with poor patient prognosis, but the cellular basis of this difference is unclear. Here,...
4.
Brockman A, Khurana R, Bartkowiak T, Thomas P, Sivagnanam S, Betts C, et al.
Cytometry B Clin Cytom
. 2023 Feb;
104(5):344-355.
PMID: 36748312
Cyclic immunohistochemistry (cycIHC) uses sequential rounds of colorimetric immunostaining and imaging for quantitative mapping of location and number of cells of interest. Additionally, cycIHC benefits from the speed and simplicity...
5.
Kaviany S, Bartkowiak T, Dulek D, Khan Y, Hayes M, Schaefer S, et al.
Immunohorizons
. 2022 Jul;
6(7):447-464.
PMID: 35840326
Patients with gain-of-function (GOF) pathogenic variants have enhanced or prolonged STAT1 phosphorylation following cytokine stimulation and exhibit increased yet heterogeneous susceptibility to infections, autoimmunity, and cancer. Although disease phenotypes are...
6.
Wilfong E, Bartkowiak T, Vowell K, Westlake C, Irish J, Kendall P, et al.
Front Immunol
. 2022 Apr;
13:756018.
PMID: 35371068
The idiopathic inflammatory myopathies (IIM) are a rare clinically heterogeneous group of conditions affecting the skin, muscle, joint, and lung in various combinations. While myositis specific autoantibodies are well described,...
7.
Marron T, Ryan A, Reddy S, Kaczanowska S, Younis R, Thakkar D, et al.
J Immunother Cancer
. 2021 Mar;
9(3).
PMID: 33653801
Immune checkpoint inhibitors (ICIs) have improved overall survival for cancer patients, however, optimal duration of ICI therapy has yet to be defined. Given ICIs were first used to treat patients...
8.
Jaiswal A, Liu A, Pudakalakatti S, Dutta P, Jayaprakash P, Bartkowiak T, et al.
Cancer Immunol Res
. 2020 Sep;
8(11):1365-1380.
PMID: 32917656
Despite the clinical success of T-cell checkpoint blockade, most patients with cancer still fail to have durable responses to immunotherapy. The molecular mechanisms driving checkpoint blockade resistance, whether preexisting or...
9.
Roussel M, Lhomme F, Roe C, Bartkowiak T, Gravelle P, Laurent C, et al.
Cancer Immunol Immunother
. 2020 Jan;
69(3):407-420.
PMID: 31919622
Tumor-associated macrophage and T-cell subsets are implicated in the pathogenesis of diffuse large B-cell lymphoma, follicular lymphoma, and classical Hodgkin lymphoma. Macrophages provide essential mechanisms of tumor immune evasion through...
10.
Roussel M, Bartkowiak T, Irish J
Methods Mol Biol
. 2019 May;
1989:217-226.
PMID: 31077108
The immune monocyte/phagocyte system (MPS) includes numerous cell subsets of the myeloid lineage including monocyte, macrophage, and dendritic cell (DC) populations that are heterogeneous both phenotypically and functionally. Previously, we...